All In Biotech

Drug Trial Radar · NCT06699628

Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers

A Single-centre, Open-label, Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers

Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12

Actual

Start

Sep 23, 2024

Primary completion

Nov 11, 2024

Study completion Nov 11, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 65 years, up to 89 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I trial evaluating the pharmacokinetics of single ascending oral doses of IRL757 in healthy elderly volunteers.

Conditions

  • Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects
  • Apathy

Interventions

  • IRL757Drug

    IRL757 capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of Maximum Plasma Concentration [Cmax] of IRL757Time frame: PK followed until 48 hours
  2. Determination of the AUC of IRL757 and Its Main MetabolitesTime frame: PK followed until 48 hours
  3. Determination of the Time for Maximum Concentration [Tmax] of IRL757 and Its Main MetabolitesTime frame: PK followed until 48 hours
  4. Determination of the Half-life [t1/2] of IRL757 and Its Main MetabolitesTime frame: PK followed until 48 hours
  5. Determination of the Renal Clearance (CLr) of IRL757Time frame: PK followed until 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CTC Clinical Trial Consultants AB

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.